The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Omalizumab for the Treatment of Multiple Food Allergies
Open accessAbstract
BACKGROUND: Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. METHODS: In this trial, we assessed whether omalizumab, a monoclonal anti-IgE antibody, would be effective and safe as monotherapy in patients with multiple food allergies. Persons 1 to 55 years of age who were allergic to peanuts and at least two other trial-specified foods (cashew, milk, egg, walnut, wheat, and hazelnut) were screened. Inclusion required a reaction to a food challenge of 100 mg or less of peanut protein and 300 mg or less of the two other foods. Participants were randomly assigned, in a 2:1 ratio, to receive omalizumab or placebo administered subcutaneously (with the dose based on weight and IgE levels) every 2 to 4 weeks for 16 to 20 weeks, after which the challenges were repeated. The primary end point was ingestion of peanut protein in a single dose of 600 mg or more without dose-limiting symptoms. The three key secondary end points were the consumption of cashew, of milk, and of egg in single doses of at least 1000 mg each without dose-limiting symptoms. The first 60 participants (59 of whom were children or adolescents) who completed this first stage were enrolled in a 24-week open-label extension. RESULTS: Of the 462 persons who were screened, 180 underwent randomization. The analysis population consisted of the 177 children and adolescents (1 to 17 years of age). A total of 79 of the 118 participants (67%) receiving omalizumab met the primary end-point criteria, as compared with 4 of the 59 participants (7%) receiving placebo (P<0.001). Results for the key secondary end points were consistent with those of the primary end point (cashew, 41% vs. 3%; milk, 66% vs. 10%; egg, 67% vs. 0%; P<0.001 for all comparisons). Safety end points did not differ between the groups, aside from more injection-site reactions in the omalizumab group. CONCLUSIONS: In persons as young as 1 year of age with multiple food allergies, omalizumab treatment for 16 weeks was superior to placebo in increasing the reaction threshold for peanut and other common food allergens. (Funded by the National Institute of Allergy and Infectious Diseases and others; ClinicalTrials.gov number, NCT03881696.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The prevalence, severity, and distribution of childhood food allergy in the United States
Gupta, R. S., Springston, E. E., Warrier, M. R., Smith, B., Kumar, R., Pongracic, J., & Holl, J. L. (2011) · PEDIATRICS · doi:10.1542/peds.2011-0204 · Cited by 1,417
The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States
Gupta, R. S., Warren, C. M., Smith, B. M., Blumenstock, J. A., Jiang, J., Davis, M. M., & Nadeau, K. C. (2018) · Pediatrics · doi:10.1542/peds.2018-1235 · Cited by 890
AR101 Oral Immunotherapy for Peanut Allergy
The PALISADE Group of Clinical Investigators (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1812856 · Cited by 765
Sampson, H. A., Gerth van Wijk, R., Bindslev-Jensen, C., Sicherer, S., Teuber, S. S., Burks, A. W., Dubois, A. E. J., Beyer, K., Eigenmann, P. A., Spergel, J. M., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.10.017 · Cited by 744
Self-citationEffect of Anti-IgE Therapy in Patients with Peanut Allergy
Leung, D. Y. M., Sampson, H. A., Yunginger, J. W., Burks, A. W., Schneider, L. C., Wortel, C. H., Davis, F. M., Hyun, J. D., & Shanahan, W. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022613 · Cited by 691
Self-citationChu, D. K., Wood, R. A., French, S., Fiocchi, A., Jordana, M., Waserman, S., Brożek, J. L., & Schünemann, H. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30420-9 · Cited by 448
Self-citationEpidemiology and Burden of Food Allergy
Warren, C. M., Jiang, J., & Gupta, R. S. (2020) · Current Allergy and Asthma Reports · doi:10.1007/s11882-020-0898-7 · Cited by 448
Wood, R. A., Kim, J. S., Lindblad, R., Nadeau, K., Henning, A. K., Dawson, P., Plaut, M., & Sampson, H. A. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.10.005 · Cited by 390
Self-citationOmalizumab facilitates rapid oral desensitization for peanut allergy
MacGinnitie, A. J., Rachid, R., Gragg, H., Little, S. V., Lakin, P., Cianferoni, A., Heimall, J., Makhija, M., Robison, R., Chinthrajah, R. S., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.08.010 · Cited by 327
Self-citationSampson, H. A., Leung, D. Y. M., Burks, A. W., Lack, G., Bahna, S. L., Jones, S. M., & Wong, D. A. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.01.051 · Cited by 298
Self-citation
Cited by
Type 2 immunity in allergic diseases
Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., et al. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01261-2 · Cited by 362
Kato, Y., Morikawa, T., & Fujieda, S. (2025) · Allergology International · doi:10.1016/j.alit.2024.08.007 · Cited by 45
Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases
Jiménez‐Saiz, R., Iborra, S., Blanco, C., González‐Pérez, R., Nuñez‐Borque, E., Zeyneloglu, C., Babayev, H., Göksel, O., Göksel, T., Khaitov, M., et al. (2026) · Allergy · doi:10.1111/all.70512 · Cited by 2
Metadata
- Authors
- Wood, R. A., Togias, A., Sicherer, S. H., Shreffler, W. G., Kim, E. H., Jones, S. M., Leung, D. Y. M., Vickery, B. P., Bird, J. A., Spergel, J. M., Iqbal, A., Olsson, J., Ligueros-Saylan, M., Uddin, A., Calatroni, A., Huckabee, C. M., Rogers, N. H., Yovetich, N., Dantzer, J., Mudd, K., Wang, J., Groetch, M., Pyle, D., Keet, C. A., Kulis, M., Sindher, S. B., Long, A., Scurlock, A. M., Lanser, B. J., Lee, T., Parrish, C., Brown-Whitehorn, T., Spergel, A. K. R., Veri, M., Hamrah, S. D., Brittain, E., Poyser, J., Wheatley, L. M., & Chinthrajah, R. S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-03-07
- Volume
- 390
- Issue
- 10
- Pages
- 889-899
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4392181751
- Cited by
- 337
- References
- 27
- FWCI
- 88.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omalizumab for the Treatment of Multiple Food Allergies. https://app.cochat.ai/papers/10.1056/nejmoa2312382
- The paper
- Wood, R. A., Togias, A., Sicherer, S. H., Shreffler, W. G., Kim, E. H., Jones, S. M., Leung, D. Y. M., Vickery, B. P., Bird, J. A., Spergel, J. M., Iqbal, A., Olsson, J., Ligueros-Saylan, M., Uddin, A., Calatroni, A., Huckabee, C. M., Rogers, N. H., Yovetich, N., Dantzer, J., . . . Chinthrajah, R. S. (2024). Omalizumab for the Treatment of Multiple Food Allergies. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2312382
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.